Quick answer: LL-37 research is mostly about how a short, positively charged peptide interacts with cell membranes and immune-related signaling in laboratory models. Most published work comes from cell and other preclinical studies, and results often depend on the experimental conditions. Our LL37 | 10mg product is supplied for laboratory research use only.
What is LL-37, also called cathelicidin LL-37?
LL-37 is a peptide of 37 amino acids. It is the active C-terminal fragment of a cathelicidin precursor protein called hCAP-18. The name comes from the two leucines (L) at the start of the chain and its 37-residue length.
It is cationic, meaning it carries a net positive charge. It is also amphipathic, meaning one side of the molecule attracts water and the other side attracts fats. In cell studies, epithelial cells, neutrophils and macrophages are described as natural sources of the peptide.
How does LL-37 interact with membranes?
This is the best-developed area of LL-37 research. Because the peptide is charged and amphipathic, researchers use it as a model for how host defense peptides meet lipid bilayers. Studies in model membranes and cultured cells have examined:
- how the peptide folds into a helical shape near membranes
- how it changes membrane permeability
- how it clusters or assembles at higher concentrations
- how its effects differ between microbial-type and host-type membranes
Many of these experiments are biophysical and can be repeated under controlled conditions. That makes this area of the evidence more reproducible than the signaling work below.
What signaling targets have researchers proposed?
In cell studies, LL-37 has been linked to several receptors and pathways. Formyl peptide receptor 2 and the P2X7 receptor are among the targets most often discussed. Researchers also report cross-talk with growth factor signaling.
This area is less settled. Reported effects vary with the cell type, the peptide concentration, the medium and the presence of other molecules. Some studies report pro-inflammatory signals and others report dampened ones, and researchers continue to study why.
Which research areas use LL-37, and how strong is the evidence?
| Research area | What researchers examine | Evidence level |
|---|---|---|
| Peptide-membrane interaction | Binding, helix formation, permeability | Substantial; model membranes and cell studies |
| Innate immune signaling | Receptor interactions, cell activation, chemotaxis | Broad cell-study base; mechanisms still debated |
| Inflammatory pathways | Cytokine signaling, pro- and anti-inflammatory balance | Context-dependent; results vary |
| Wound and tissue models | Cell migration, extracellular matrix interaction | Preclinical; early |
| Angiogenesis and vascular signaling | Endothelial cell responses | Preclinical; limited |
Across all of these areas, the evidence is laboratory-based. It describes what the peptide does in a dish or in a preclinical model. It should not be read as a statement about what the product does for anyone.
What is still unknown about LL-37?
- Concentration dependence. Cell studies suggest the same peptide can behave differently across concentrations, and the boundaries are not fully mapped.
- Stability. Published stability depends heavily on the medium and on enzymes present, so we do not quote a single half-life.
- Conflicting signals. The balance between pro- and anti-inflammatory effects is not settled.
- Translation. Findings from cultured cells do not automatically carry over to more complex systems.
What is in the LL37 10mg vial?
- Peptide name: LL-37 (alternate name: Cathelicidin LL-37)
- Size: 10mg
- CAS number: 143723-48-4
- Molecular formula: C₂₀₅H₃₁₆N₆₀O₆₃
- Molecular weight: about 4493.3 g/mol
- Length: 37 amino acids
Our peptides are synthesized at a WHO/GMP and ISO 9001 certified laboratory in California. For why vial sizes differ, see why the same peptide comes in 2mg, 5mg, and 10mg vials.
How is LL-37 tested?
The Certificate of Analysis for this lot should show three things: identity by mass spectrometry, purity by HPLC, and peptide content per vial. For LL-37, the expected mass is about 4493.3 g/mol.
At this size, mass spectrometry often reports several charged forms of the same molecule rather than one clean peak. A reader should expect to see that pattern on the report.
LL-37 is also a long, charged and partly hydrophobic sequence. Peptides like this can pick up truncated or deleted sequences during synthesis and can aggregate. A purity figure alone does not rule those out, so identity and content matter as much as purity. Our article on why mass matters more than purity explains that point. For a general walkthrough, see our line-by-line COA guide.
Frequently asked questions
What does the name LL-37 stand for?
The two letters are the first two amino acids, both leucine. The number is the peptide's length of 37 residues.
Is LL-37 the same as cathelicidin?
Not exactly. Cathelicidin is the name of a family of host defense peptides, and LL-37 is the 37-residue active fragment released from the precursor hCAP-18.
Why is LL-37 called amphipathic?
Its structure has a water-attracting face and a fat-attracting face. This is why researchers use it to study how peptides meet lipid membranes.
Why do LL-37 studies sometimes disagree?
Reported effects change with cell type, concentration and the surrounding medium. Researchers are still working out how these factors interact.
What is the CAS number for LL-37?
The CAS number listed for our product is 143723-48-4.
Is LL37 10mg sold for personal use?
No. It is supplied strictly for in vitro and preclinical laboratory research.
Every lot we sell has a Certificate of Analysis you can read before you order. Questions before you buy? Our team is in Chandler, Arizona: (888) 745-1505 or our contact page.
View LL37 | 10mgAll products sold by BioPure Peptides are intended strictly for in-vitro laboratory and research use only. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.
